

**Botulinum Toxins Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_

**Drug Information**

**Dose:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_ **Start Date:** \_\_\_\_\_  
**HPCS Code:** \_\_\_\_\_ **Billing Units Per Dose:** \_\_\_\_\_ **J.W. Units:** \_\_\_\_\_  
**CPT Code:** \_\_\_\_\_ **Member's Weight:** \_\_\_\_\_

**Billing Provider Information**

**Provider NPI:** \_\_\_\_\_ **Provider Name:** \_\_\_\_\_  
**Provider Phone:** \_\_\_\_\_ **Provider Fax:** \_\_\_\_\_

**Prescriber Information**

**Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_  
**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_

**Clinical Information**

**\*Page 1 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.\***

**Diagnosis:** \_\_\_\_\_ (Diagnosis is required for all Botulinum Toxins)

**Please note: Botox® and Dysport® are the preferred products for SoonerCare**

**Chronic Migraine Diagnosis:** Please complete the following section. (Only Botox® will be approved.)

1. Have the following medical conditions known to cause or exacerbate migraines been ruled out/treated?
  - a. Increased intracranial pressure (e.g., tumor, pseudotumor cerebri, central venous thrombosis)? Yes \_\_\_ No \_\_\_
  - b. Decreased intracranial pressure (e.g., post-lumbar puncture headache, dural tear after trauma)? Yes \_\_\_ No \_\_\_
2. Has migraine headache exacerbation secondary to the following medication therapies or conditions been ruled out and/or treated?
  - a. Hormone replacement therapy or hormone-based contraceptives? Yes \_\_\_ No \_\_\_
  - b. Chronic insomnia? Yes \_\_\_ No \_\_\_
  - c. Obstructive sleep apnea? Yes \_\_\_ No \_\_\_
3. Does member have any contraindications to Botox injections? Yes \_\_\_ No \_\_\_
4. Number of headache days per month? \_\_\_\_\_
5. Number of migraine days per month? \_\_\_\_\_
  - a. How long has the member had chronic migraines at the frequency listed above? \_\_\_\_\_ months
6. What is the average duration of migraines? \_\_\_\_\_ hours
7. Has the member failed at least 2 different types of medications typically used for migraine prevention [e.g., select antihypertensives (such as beta-blockers), select anticonvulsants (such as valproate or topiramate), select antidepressants (such as amitriptyline or venlafaxine)]? Yes \_\_\_ No \_\_\_ If yes, please list:
 

Medication _____	Date Span _____	Dosing _____
Medication _____	Date Span _____	Dosing _____
8. Is the member taking any of the following medications known to cause medication overuse or rebound headaches in the absence of intractable conditions known to cause chronic pain?
  - a. Decongestants (alone or in combination products)? Yes \_\_\_ No \_\_\_
  - b. Combination analgesics containing caffeine and/or butalbital? Yes \_\_\_ No \_\_\_
  - c. Opioid-containing medications? Yes \_\_\_ No \_\_\_
  - d. Analgesic medications including acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs)? Yes \_\_\_ No \_\_\_
  - e. Ergotamine-containing medications? Yes \_\_\_ No \_\_\_
  - f. Triptans? Yes \_\_\_ No \_\_\_
9. If member is taking any of the medication(s) listed in Question 8, please list the medication(s) and the number of days per month taken: \_\_\_\_\_
10. If member is taking any of the medication(s) listed in Question 8, please provide additional information to support member's need for continued use of medication(s) known to cause overuse or rebound headaches: \_\_\_\_\_

**PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:**

University of Oklahoma College of Pharmacy  
 Pharmacy Management Consultants  
 Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
 Phone: 1-800-522-0114 Option 4

**CONFIDENTIALITY NOTICE**

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*

# Botulinum Toxins Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

## Clinical Information

**\*Page 2 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.\***

### Chronic Migraine Diagnosis Continued:

- Is the member taking any medications that are likely to be the cause of the headaches? Yes \_\_\_ No \_\_\_
- Has the member been evaluated by a neurologist for chronic migraine headaches within the past 6 months?  
Yes \_\_\_ No \_\_\_ If yes, please include name of neurologist recommending Botox® treatment: \_\_\_\_\_
- If applicable, are other aggravating factors that contribute to the development of episodic/chronic migraine headaches being treated (e.g., smoking)? Yes \_\_\_ No \_\_\_ NA \_\_\_
- Will member use botulinum toxin concurrently with a calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine? Yes \_\_\_ No \_\_\_

### Overactive Bladder Diagnosis: Please complete the following section. (Only Botox® will be approved.)

- Number of urinary incontinence episode(s) per day while on medication? \_\_\_\_\_
- Have urodynamic studies been performed? Yes \_\_\_ No \_\_\_ If yes, include date \_\_\_\_\_
- Has member participated in behavioral therapy? Yes \_\_\_ No \_\_\_  
If yes, please give length of therapy and reason for therapy failure: \_\_\_\_\_
- Has member used at least 3 anti-muscarinic medications for the treatment of overactive bladder? Yes \_\_\_ No \_\_\_  
If yes, please list:  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_
- Does the member or caregiver have the ability to catheterize? Yes \_\_\_ No \_\_\_

### Neurogenic Bladder Diagnosis: Please complete the following section. (Only Botox® will be approved.)

- Have urodynamic studies been performed? Yes \_\_\_ No \_\_\_ If yes, include date \_\_\_\_\_
- What is the specific underlying pathological urologic dysfunction (such as small bladder capacity <400 cc, high detrusor pressure, etc)? \_\_\_\_\_
- Does member keep diary of fluid intake, voiding/catheterization times and amounts or number of diapers/pads used daily? Yes \_\_\_ No \_\_\_
- Clinical reason for failure of anticholinergic medication therapy? \_\_\_\_\_
- Does the member have physical and cognitive ability to self-catheterize or access to caregiver? Yes \_\_\_ No \_\_\_

Page 2 of 2

Please complete and return all pages. Failure to complete all pages will result in processing delays.

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.*

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*